SAN DIEGO, Feb. 16, 2018 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a
biotechnology company developing innovative products to fill
women's unmet healthcare needs, today announced that Saundra Pelletier, CEO, will present at the 2018
RBC Capital Markets Global Healthcare Conference as follows:
Date:
|
Wednesday, February
21, 2018
|
|
|
Time:
|
11:30 a.m. Eastern
Standard Time
|
|
|
Location:
|
Lotte New York Palace
Hotel, New York
|
The presentation will be webcast live at the aforementioned time
via the Company's website at www.evofem.com under the "Investors"
section.
Evofem's lead product candidate, Amphora® (L-lactic
acid, citric acid, and potassium bitartrate) vaginal gel, is being
studied as an on-demand, non-hormonal vaginal contraceptive and for
the prevention of certain sexually transmitted infections (STIs).
The Company completed enrollment ahead of schedule in its
confirmatory Phase 3 clinical trial of Amphora for contraception,
and expects to report study data in the first quarter of
2019. Recruitment is ongoing in a Phase 2b/3 clinical trial of Amphora to prevent
urogenital chlamydia and gonorrhea in women.
About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a biotechnology
company that develops and anticipates commercializing innovative
products to address unmet needs in women's sexual and reproductive
health. For more information regarding Evofem, visit
www.evofem.com.
Forward-Looking Statements
Statements in this press release about Evofem's future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements about the results of the Phase 3
contraceptive clinical trial and any expected completion date for
this clinical trial as well as statements about the results of the
Phase 2b/3 STI clinical trial and any
expected completion date for this clinical trial.
Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including whether Evofem will be able to raise the
additional funding necessary to complete its clinical trials,
including the Phase 3 contraceptive clinical trial of Amphora and
the Phase 2b/3 STI clinical trial;
whether Evofem's product candidates will advance through the
clinical trial process on a timely basis, according to presently
contemplated schedules or at all; whether Evofem's product
candidates will receive approval from regulatory agencies on a
timely basis or at all; whether, if product candidates obtain
approval, they will be successfully distributed and marketed and
other factors discussed in the "Risk Factors-Risks Related to
Evofem" section of a registration statement on Form S-4 initially
filed with the Securities and Exchange Commission (the SEC) by
Evofem Biosciences, Inc. (formerly known as Neothetics, Inc.) on
November 15, 2017, a copy of which is
available on the Evofem website. In addition, the forward-looking
statements included in this press release represent Evofem's views
as of the date hereof. Evofem anticipates that subsequent events
and developments will cause its views to change. However, while
Evofem may elect to update these forward-looking statements at some
point in the future, it specifically disclaims any obligation to do
so. These forward-looking statements should not be relied upon as
representing Evofem's views as of any date subsequent to the date
hereof.
Evofem Biosciences' Contact
Amy Raskopf
Investor Relations
araskopf@evofem.com
858-550-1900 x167
View original content with
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-rbc-global-healthcare-conference-300599949.html
SOURCE Evofem Biosciences, Inc.